The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

Abstract

In December 2008, to accelerate understanding of a new agent, the Association of British Clinical Diabetologists (ABCD) launched a nationwide audit on the use of exenatide in clinical practice. A password‐protected online questionnaire for collection of anonymised patient data was established and diabetes specialists in the UK were given persistent encouragement to submit data on their exenatide‐treated patients. Baseline and latest HbA1c, weight, body mass index (BMI), waist circumference, blood pressure and lipids were compared and adverse events related to exenatide were quantified. A total of 315 contributors from 126 centres submitted data on 6717 patients (54.9% male) – mean baseline age was 54.9 years, HbA1c 9.47% (80mmol/mol), weight 113.8kg, BMI 39.8kg/m2. Of these, 4551 and 4385 had dated baseline and latest HbA1c and weight respectively. Mean (±SE) HbA1c fell by 0.73±0.03% (p<0.001) and weight by 5.9±0.1kg (p<0.001) at a median (range) of 26.1(6.6–164.1) and 26.0(6.6–159.0) weeks respectively. The following parameters also showed significant falls (p<0.001): BMI 2.2±0.1kg/m2, waist circumference 5.1±0.3cm, systolic blood pressure 3.6±0.6mmHg, total cholesterol 0.16±0.03mmol/L and HDL cholesterol 0.03±0.01mmol/L. Triglycerides decreased by 0.14±0.06mmol/L (p=0.009). The change in diastolic blood pressure was not statistically significant. In all, 23.7% of patients reported gastrointestinal side effects with 7.2% having to stop exenatide permanently. Hypoglycaemia rates were 3.3% before and 5.6% after exenatide use (p<0.001). After scrutiny, one case of pancreatitis and four cases of renal failure occurring in patients on exenatide had no obvious alternate cause. All other reported side effects had <1% incidence. The rate of exenatide discontinuation was 19.9% throughout the span of the audit, most commonly due to gastrointestinal side effects (36.1%) and lack of glycaemic or weight benefit (33.8%). This large scale audit confirmed the effectiveness of exenatide in clinical use and highlighted rare associated adverse events. Importantly, we have successfully demonstrated a novel approach by a national specialist society to independently monitor the efficacy and safety of a new treatment. Copyright © 2010 John Wiley & Sons.

GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice

“…14 Patients in the liraglutide audit had mean ± SD BMI of 38.8 kg/m 2 ± 7.2 and HbA1c of 9.39% ± 1.72 and 39.2% of patients were on insulin at liraglutide initiation. We think that the baseline characteristics of patients in the audit were influenced by NICE guidelines (recommending selection of patients with higher BMI) as well as the predominant participation and use of GLP-1ra therapies in specialist practice dealing with patients with more advanced diabetes.…”

Liraglutide pancreatitis: The ABCD nationwide liraglutide audit

“…27 It is clear that clinicians in the UK who are treating patients with exenatide and liraglutide, see considerable benefits in terms of reductions in weight and Hba1c; and reduction in other therapies, including insulin. 23,33,34 This audit is in keeping with the everyday experience of clinicians who treat 'real-world' Type 2 diabetes patients on a daily basis and who see benefits with these agents. Those same clinicians hardly ever find their exenatide and liraglutide-treated patients experiencing acute pancreatitis, and when they do, Comparison between the reported rates of acute pancreatitis (cases/100 patient-years of exposure) in the ABCD Nationwide Liraglutide Audit and those in the combined clinical trials of liraglutide, 30 including the rates of those on active comparators in those trials.…”

Diabetes requiring insulin – recent developments in management

“…Although exenatide was less effective in lowering HbA 1c among insulin-treated patients, a significant number of these insulin-treated patients still achieved significant reductions in HbA 1c , weight and insulin doses. 21,22 There is extremely limited evidence for the use of GLP-1 agonists along with insulin in long-standing type 1 diabetes and this is currently not licensed. One small trial of 11 patients on CSII treatment showed a weight loss of 4.2 per cent and a reduction in insulin requirement of 19.2 per cent when liraglutide was added.…”